Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
NCT ID: NCT00352183
Last Updated: 2009-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
450 participants
INTERVENTIONAL
2006-01-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
NCT00349375
Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin
NCT00362934
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
NCT00362206
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
NCT01674712
A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome
NCT00349284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Fenofibrate/Simvastatin
Combination of Fenofibrate and Simvastatin 40mg
2
Simvastatin
Simvastatin 40mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fenofibrate/Simvastatin
Combination of Fenofibrate and Simvastatin 40mg
Simvastatin
Simvastatin 40mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known hypersensitivity to fenofibrate or simvastatin,
* Pregnant or lactating women,
* Contra-indication to fenofibrate or simvastatin,
* Unstable or severe cardiac disease.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 204
Adelaide, , Australia
Site 214
Adelaide, , Australia
Site 203
Bendigo, , Australia
Site 207
Brisbane, , Australia
Site 208
Brisbane, , Australia
Site 221
Brisbane, , Australia
Site 202
Burnie, , Australia
Site 201
Camperdown, , Australia
Site 220
Coffs Harbour, , Australia
Site 218
Daw Park, , Australia
Site 212
Elizabeth Vale, , Australia
Site 217
Fitzroy, , Australia
Site 222
Fremantle, , Australia
Site 216
Geelong, , Australia
Site 225
Ingleburn, , Australia
Site 213
Kippa-Ring, , Australia
Site 209
Launceston, , Australia
Site 219
Liverpool, , Australia
Site 223
Malvern, , Australia
Site 211
Meadowbrook, , Australia
Site 224
Miranda, , Australia
Site 210
Nambour, , Australia
Site 205
Parkville, , Australia
Site 206
Sale, , Australia
Site 215
Sydney, , Australia
Site 301
Tallinn, , Estonia
Site 302
Tallinn, , Estonia
Site 303
Tallinn, , Estonia
Site 305
Tallinn, , Estonia
Site 306
Tallinn, , Estonia
Site 304
Tartu, , Estonia
Site 307
Tartu, , Estonia
Site 603
Balatonfüred, , Hungary
Site 605
Budapest, , Hungary
Site 608
Budapest, , Hungary
Site 604
Gyöngyös, , Hungary
Site 602
Győr, , Hungary
Site 610
Hódmezővásárhely, , Hungary
Site 609
Kecskemét, , Hungary
Site 601
Miskolc, , Hungary
Site 607
Sopron, , Hungary
Site 606
Székesfehérvár, , Hungary
Site 403
Daugavpils, , Latvia
Site 406
Jēkabpils, , Latvia
Site 401
Ogre, , Latvia
Site 402
Riga, , Latvia
Site 405
Riga, , Latvia
Site 404
Tukums, , Latvia
Site 502
Alytus, , Lithuania
Site 503
Kaunas, , Lithuania
Site 506
Kaunas, , Lithuania
Site 505
Klaipėda, , Lithuania
Site 507
Klaipėda, , Lithuania
Site 508
Palanga, , Lithuania
Site 504
Šiauliai, , Lithuania
Site 501
Vilnius, , Lithuania
Site 102
Auckland, , New Zealand
Site 103
Auckland, , New Zealand
Site 107
Blenheim, , New Zealand
Site 101
Christchurch, , New Zealand
Site 108
Dunedin, , New Zealand
Site 104
Hamilton, , New Zealand
Site 111
Hastings, , New Zealand
Site 106
Nelson, , New Zealand
Site 110
Newtown, Wellington, , New Zealand
Site 109
Takapuna, Auckland, , New Zealand
Site 105
Tauranga, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTRN012605000777695
Identifier Type: -
Identifier Source: secondary_id
C LF0242780-01 05 02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.